|
1
|
Fisher JL, Schwartzbaum JA, Wrensch M and
Wiemels JL: Epidemiology of brain tumors. Neurol Clin. 25:867–890.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bondy ML, Scheurer ME, Malmer B,
Barnholtz-Sloan JS, Davis FG, Il'yasova D, Kruchko C, McCarthy BJ,
Rajaraman P, Schwartzbaum JA, et al: Brain tumor epidemiology:
Consensus from the brain tumor epidemiology consortium. Cancer. 113
(Suppl 7):S1953–S1968. 2008. View Article : Google Scholar
|
|
3
|
Feng J, Kim ST, Liu W, Kim JW, Zhang Z,
Zhu Y, Berens M, Sun J and Xu J: An integrated analysis of germline
and somatic, genetic and epigenetic alterations at 9p21.3 in
glioblastoma. Cancer. 118:232–240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caserta S, Kern F, Cohen J, Drage S,
Newbury SF and Llewelyn MJ: Circulating plasma microRNAs can
differentiate human sepsis and systemic inflammatory response
syndrome (SIRS). Sci Rep. 6:280062016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McClure C, McPeak MB, Youssef D, Yao ZQ,
McCall CE and El Gazzar M: Stat3 and C/EBPβ synergize to induce
miR-21 and miR-181b expression during sepsis. Immunol Cell Biol.
95:42–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rolle K: miRNA Multiplayers in glioma:
From bench to bedside. Acta Biochim Pol. 62:353–365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Browne G, Dragon JA, Hong D, Messier TL,
Gordon JA, Farina NH, Boyd JR, VanOudenhove JJ, Perez AW, Zaidi SK,
et al: MicroRNA-378-mediated suppression of Runx1 alleviates the
aggressive phenotype of triple-negative MDA-MB-231 human breast
cancer cells. Tumour Biol. 37:8825–8839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mirzaei H, Khataminfar S, Mohammadparast
S, Sales SS, Maftouh M, Mohammadi M, Simonian M, Parizadeh SM,
Hassanian SM and Avan A: Circulating microRNAs as potential
diagnostic biomarkers and therapeutic targets in gastric cancer:
Current status and future perspectives. Curr Med Chem.
23:4135–4150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng J, Xie Z, Cheng L, Zhang Y, Chen J,
Yu H, Li Z and Kang H: Paired design study by real-time PCR:
miR-378* and miR-145 are potent early diagnostic biomarkers of
human colorectal cancer. BMC Cancer. 15:1582015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scapoli L, Palmieri A, Lo Muzio L,
Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and
Carinci F: MicroRNA expression profiling of oral carcinoma
identifies new markers of tumor progression. Int J Immunopathol
Pharmacol. 23:1229–1234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu XW, Wen XM, Zhang YY, Yang L, Guo H,
Yang J, Zhang M, Yin JY, Ma JC, Lin J, et al: The 5′flanking region
of miR-378 is hypomethylated in acute myeloid leukemia. Int J Clin
Exp Pathol. 8:4321–4331. 2015.PubMed/NCBI
|
|
13
|
Li B, Wang Y, Li S, He H, Sun F, Wang C,
Lu Y, Wang X and Tao B: Decreased expression of miR-378 correlates
with tumor invasiveness and poor prognosis of patients with glioma.
Int J Clin Exp Pathol. 8:7016–7021. 2015.PubMed/NCBI
|
|
14
|
Arita H, Yamasaki K, Matsushita Y,
Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M,
Shimizu S, et al: A combination of TERT promoter mutation and MGMT
methylation status predicts clinically relevant subgroups of newly
diagnosed glioblastomas. Acta Neuropathol Commun. 4:792016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Turkalp Z, Karamchandani J and Das S: IDH
mutation in glioma: New insights and promises for the future. JAMA
Neurol. 71:1319–1325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mulholland S, Pearson DM, Hamoudi RA,
Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund
LM, Collins VP and Ichimura K: MGMT CpG island is invariably
methylated in adult astrocytic and oligodendroglial tumors with
IDH1 or IDH2 mutations. Int J Cancer. 131:1104–1113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okita Y, Narita Y, Miyakita Y, Ohno M,
Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T and Shibui
S: IDH1/2 mutation is a prognostic marker for survival and predicts
response to chemotherapy for grade II gliomas concomitantly treated
with radiation therapy. Int J Oncol. 41:1325–1336. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arita H, Narita Y, Matsushita Y, Fukushima
S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S and Ichimura
K: Development of a robust and sensitive pyrosequencing assay for
the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol.
32:22–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arita H, Narita Y, Fukushima S, Tateishi
K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP,
Kawahara N, et al: Upregulating mutations in the TERT promoter
commonly occur in adult malignant gliomas and are strongly
associated with total 1p19q loss. Acta Neuropathol. 126:267–276.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Skup M, Dwornik A, Macias M, Sulejczak D,
Wiater M and Czarkowska-Bauch J: Long-term locomotor training
upregulates TrkBFL receptor-like proteins, brain-derived
neurotrophic factor, and neurotrophin 4 with different topographies
of expression in oligodendroglia and neurons in the spinal cord.
Exp Neurol. 176:289–307. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Minemura H, Takagi K, Miki Y, Shibahara Y,
Nakagawa S, Ebata A, Watanabe M, Ishida T, Sasano H and Suzuki T:
Abnormal expression of miR-1 in breast carcinoma as a potent
prognostic factor. Cancer Sci. 106:1642–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu T, Li YS, Chen B, Chang YF, Liu GC,
Hong Y, Chen HL and Xiyang YB: Elevated glucose-6-phosphate
dehydrogenase expression in the cervical cancer cases is associated
with the cancerigenic event of high-risk human papillomaviruses.
Exp Biol Med (Maywood). 240:1287–1297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang L, Wong CM, Ying Q, Fan DN, Huang S,
Ding J, Yao J, Yan M, Li J, Yao M, et al: MicroRNA-125b suppressed
human liver cancer cell proliferation and metastasis by directly
targeting oncogene LIN28B2. Hepatology. 52:1731–1740. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He Z, Xia Y, Liu B, Qi X, Li Z, Wang J,
Chen L and Chen Y: Down-regulation of miR-452 is associated with
poor prognosis in the non-small-cell lung cancer. J Thorac Dis.
8:894–900. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Z, Piao YS, Zhang LY, Wang LM, Wang DD,
Fu YJ, Cai YN and Lu DH: Application of ATRX in diagnosis and
prognostic evaluation of glioma. Zhonghua Bing Li Xue Za Zhi.
46:690–694. 2017.(In Chinese). PubMed/NCBI
|
|
27
|
Krist B, Florczyk U,
Pietraszek-Gremplewicz K, Józkowicz A and Dulak J: The role of
miR-378a in metabolism, angiogenesis, and muscle biology. Int J
Endocrinol. 2015:2817562015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eichner LJ, Perry MC, Dufour CR, Bertos N,
Park M, St-Pierre J and Giguère V: miR-378(∗) mediates
metabolic shift in breast cancer cells via the PGC-1β/ERRγ
transcriptional pathway. Cell Metab. 12:352–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kasashima K, Nakamura Y and Kozu T:
Altered expression profiles of microRNAs during TPA-induced
differentiation of HL-60 cells. Biochem Biophys Res Commun.
322:403–410. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei X, Li H, Zhang B, Li C, Dong D, Lan X,
Huang Y, Bai Y, Lin F, Zhao X and Chen H: miR-378a-3p promotes
differentiation and inhibits proliferation of myoblasts by
targeting HDAC4 in skeletal muscle development. RNA Biol.
13:1300–1309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Greco S, Perfetti A, Fasanaro P, Cardani
R, Capogrossi MC, Meola G and Martelli F: Deregulated microRNAs in
myotonic dystrophy type 2. PLoS One. 7:e397322012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang N, Wang J, Xie W, Lyu Q, Wu J, He J,
Qiu W, Xu N and Zhang Y: miR-378a-3p enhances adipogenesis by
targeting mitogen-activated protein kinase 1. Biochem Biophys Res
Commun. 457:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trelinska J, Fendler W, Dachowska I,
Kotulska K, Jozwiak S, Antosik K, Gnys P, Borowiec M and Mlynarski
W: Abnormal serum microRNA profiles in tuberous sclerosis are
normalized during treatment with everolimus: Possible clinical
implications. Orphanet J Rare Dis. 11:1292016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hyun J, Wang S, Kim J, Rao KM, Park SY,
Chung I, Ha CS, Kim SW, Yun YH and Jung Y: MicroRNA-378 limits
activation of hepatic stellate cells and liver fibrosis by
suppressing Gli3 expression. Nat Commun. 7:109932016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikeda K, Horie-Inoue K, Ueno T, Suzuki T,
Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H and
Inoue S: miR-378a-3p modulates tamoxifen sensitivity in breast
cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 5:131702015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kara M, Yumrutas O, Ozcan O, Celik OI,
Bozgeyik E, Bozgeyik I and Tasdemir S: Differential expressions of
cancer-associated genes and their regulatory miRNAs in colorectal
carcinoma. Gene. 567:81–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Megiorni F, Cialfi S, McDowell HP, Felsani
A, Camero S, Guffanti A, Pizer B, Clerico A, De Grazia A, Pizzuti
A, et al: Deep sequencing the microRNA profile in rhabdomyosarcoma
reveals down-regulation of miR-378 family members. BMC Cancer.
14:8802014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li H, Dai S, Zhen T, Shi H, Zhang F, Yang
Y, Kang L, Liang Y and Han A: Clinical and biological significance
of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer.
50:1207–1221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Masse I, Agaësse G and Berthier-Vergnes O:
Tetraspanins in cutaneous physiopathology. Med Sci (Paris).
32:267–273. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hölters S, Anacker J, Jansen L,
Beer-Grondke K, Dürst M and Rubio I: Tetraspanin 1 promotes
invasiveness of cervical cancer cells. Int J Oncol. 43:503–512.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
He P, Wang S, Zhang X, Gao Y, Niu W, Dong
N, Shi X, Geng Y, Ma Q, Li M, et al: Tspan5 is an independent
favourable prognostic factor and suppresses tumour growth in
gastriccancer. Oncotarget. 7:40160–40173. 2016.PubMed/NCBI
|
|
42
|
Yang YG, Sari IN, Zia MF, Lee SR, Song SJ
and Kwon HY: Tetraspanins: Spanning from solid tumors to
hematologic malignancies. Exp Hematol. 44:322–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang XF, Gao GD, Liu J, Guo R, Lin YX, Chu
YL, Han FC, Zhang WH and Bai YJ: Identification of differentially
expressed genes induced by angiotensin II in rat cardiac
fibroblasts. Clin Exp Pharmacol Physiol. 33:41–46. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hou FQ, Lei XF, Yao JL, Wang YJ and Zhang
W: Tetraspanin 1 is involved in survival, proliferation and
carcinogenesis of pancreatic cancer. Oncol Rep. 34:3068–3076. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Haining EJ, Yang J, Bailey RL, Khan K,
Collier R, Tsai S, Watson SP, Frampton J, Garcia P and Tomlinson
MG: The TspanC8 subgroup of tetraspanins interacts with A
disintegrin and metalloprotease 10 (ADAM10) and regulates its
maturation and cell surface expression. J Biol Chem.
287:39753–39765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang YA, Zhou Y, Luo X, Song K, Ma X,
Sathe A, Girard L, Xiao G and Gazdar AF: SHOX2 is a potent
independent biomarker to predict survival of WHO grade II–III
diffuse gliomas. EBioMedicine. 13:80–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
